Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pawel Lewek is active.

Publication


Featured researches published by Pawel Lewek.


Frontiers in Pharmacology | 2013

Determinants of patient adherence: a review of systematic reviews.

Przemyslaw Kardas; Pawel Lewek; Michał Matyjaszczyk

Purpose: A number of potential determinants of medication non-adherence have been described so far. However, the heterogenic quality of existing publications poses the need for the use of a rigorous methodology in building a list of such determinants. The purpose of this study was a systematic review of current research on determinants of patient adherence on the basis of a recently agreed European consensus taxonomy and terminology. Methods: MEDLINE, EMBASE, CINAHL, Cochrane Library, IPA, and PsycINFO were systematically searched for systematic reviews published between 2000/01/01 and 2009/12/31 that provided determinants on non-adherence to medication. The searches were limited to reviews having adherence to medication prescribed by health professionals for outpatient as a major topic. Results: Fifty-one reviews were included in this review, covering 19 different disease categories. In these reviews, exclusively assessing non-adherence to chronic therapies, 771 individual factor items were identified, of which most were determinants of implementation, and only 47—determinants of persistence with medication. Factors with an unambiguous effect on adherence were further grouped into 8 clusters of socio-economic-related factors, 6 of healthcare team- and system-related factors, 6 of condition-related factors, 6 of therapy-related factors, and 14 of patient-related factors. The lack of standardized definitions and use of poor measurement methods resulted in many inconsistencies. Conclusions: This study provides clear evidence that medication non-adherence is affected by multiple determinants. Therefore, the prediction of non-adherence of individual patients is difficult, and suitable measurement and multifaceted interventions may be the most effective answer toward unsatisfactory adherence. The limited number of publications assessing determinants of persistence with medication, and lack of those providing determinants of adherence to short-term treatment identify areas for future research.


Expert Opinion on Drug Safety | 2016

Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments.

Derek Stewart; Alpana Mair; Martin Wilson; Przemyslaw Kardas; Pawel Lewek; Albert Alonso; Jennifer McIntosh; Katie MacLure

ABSTRACT Introduction: Single disease state led evidence-based guidelines do not provide sufficient coverage of issues of multimorbidities, with the cumulative impact of recommendations often resulting in overwhelming medicines burden. Inappropriate polypharmacy increases the likelihood of adverse drug events, drug interactions and non-adherence. Areas covered: A detailed description of a pan-European initiative, ‘Stimulating Innovation Management of Polypharmacy and Adherence in the Elderly, SIMPATHY’, which is a project funded by the European Commission to support innovation across the European Union. This includes a systematic review of the literature aiming to summarize and review critically current policies and guidelines on polypharmacy management in older people. The policy driven, evidence-based approach to managing inappropriate polypharmacy in Scotland is described, with consideration of a change management strategy based on Kotter’s eight step process for leading sustainable change. Expert opinion: The challenges around promoting appropriate polypharmacy are on many levels, primarily clinical, organisational and political, all of which any workable solution will need to address. To be effective, safe and efficient, any programme that attempts to deal with the complexities of prescribing in this population must be patient-centred, clinically robust, multidisciplinary and designed to fit into the healthcare system in which it is delivered.


Acupuncture in Medicine | 2012

An acupuncture needle remaining in a lung for 17 years: case study and review

Pawel Lewek; Joanna Lewek; Przemyslaw Kardas

The case of a 67-year-old patient with an acupuncture needle remaining in his left lung is described. This foreign body was a remnant of a procedure performed by a doctor 17 years previously for osteoarthritic back pain. On the basis of this case, a review was performed of literature available in the PubMed database dealing with acupuncture needles remaining in a patients body. A total of 25 articles were found. The articles describe needles found in the bladder, shoulder girdle, spinal cord, right ventricle, L5 nerve root, medulla oblongata, skin, carpal tunnel, nuchal and occipital area, calf and paraspinal muscle. Migration of needle fragments to the liver, pancreas, stomach, colon, breast, kidney, muscles, and spinal cord has been reported in the literature. In cases where patients were operated on, the needles were removed without subsequent complications and the patients recovered fully.


International Journal of Behavioral Medicine | 2015

Systematic Review of Clinical Practice Guidelines for the Improvement of Medication Adherence

Todd M. Ruppar; Fabienne Dobbels; Pawel Lewek; Michał Matyjaszczyk; Kaat Siebens; Sabina De Geest

BackgroundPoor adherence to medications is a significant problem that leads to increased morbidity, mortality, and health care costs. Recommended approaches to address medication adherence vary, and existing practice guidelines are unclear.PurposeThis review evaluated clinical practice guidelines designed to help health care providers address patients’ medication adherence.MethodMultiple search methods were used to identify national or international guidelines addressing medication adherence. We included guidelines published in English, as well as guidelines with an English-language summary or translation.ResultsWe identified 23 guidelines of varying detail and quality. Recommendations were categorized as assessment strategies (n = 20 guidelines); educational strategies (n = 18); behavioral strategies (n = 17); therapeutic relationship, communication, and provider factors (n = 19); and addressing outside influences/co-morbidities (n = 10).ConclusionFuture guidelines should be more clearly guided by research findings and comparative effectiveness methods. When implemented, guidelines will facilitate health care providers and health systems in supporting optimal adherence and improved health outcomes.


Bosnian Journal of Basic Medical Sciences | 2014

Factors affecting the opinions of family physicians regarding generic drugs – a questionnaire based study

Pawel Lewek; Janusz Smigielski; Przemyslaw Kardas

A range of factors are believed to exert a negative influence on opinions of physicians about generic drugs.The aim of this study was to survey the opinions of primary care doctors on generics, and determine the factors which may affect them. A questionnaire comprising thirty eight questions was distributed among primary care doctors working in seventy out-patient clinics of the Lodzkie province, Poland, during the period of January 1, 2010 - December 31, 2010. A total of 170 of 183 participants completed the survey (average age 48.5; 70.0% women): a 92.9% response rate. While 38.8% of physicians claimed that generics were worse than brand name drugs, 54.1% considered them to be better. However, 36.5% of the doctors did not choose generics for their own use. Two key opinions were identified among the responses concerning the effectiveness of generic drugs: use of generic drugs by the physician (p<0.001), and their opinion that pharmacists do inform patients about generic drugs (p<0.05). Although existing evidence confirms that generic and brand name drugs are equally effective, many physicians doubt this, which prevents them from being used as cost effective drug therapy. In order to increase healthcare savings through the use of generics, these factors should be addressed: for example, convincing a physician to adopt generics for personal use may be an efficient way to support more cost effective treatment of his patients.


PLOS ONE | 2017

A modified Delphi study to determine the level of consensus across the European Union on the structures, processes and desired outcomes of the management of polypharmacy in older people

Derek Stewart; Kathrine Gibson-Smith; Katie MacLure; Alpana Mair; Albert Alonso; Carles Codina; Antonio Cittadini; Fernando Fernandez-Llimos; Glenda Fleming; Dimitra Gennimata; Ulrike Gillespie; Cathy Harrison; Ulrika Junius-Walker; Przemyslaw Kardas; Thomas Kempen; Moira Kinnear; Pawel Lewek; João O. Malva; Jennifer McIntosh; Claire Scullin; Birgitt Wiese

Background Inappropriate use of multiple medicines (inappropriate polypharmacy) is a major challenge in older people with consequences of increased prevalence and severity of adverse drug reactions and interactions, and reduced medicines adherence. The aim of this study was to determine the levels of consensus amongst key stakeholders in the European Union (EU) in relation to aspects of the management of polypharmacy in older people. Methods Forty-six statements were developed on aspects of healthcare structures, processes and desired outcomes, with consensus defined at ≥ 80% agreement. Panel members were strategists (e.g. directors, leading clinicians and commissioners) from each of the 28 EU member states, with a target recruitment of five per member state. Three Delphi rounds were conducted via email, with panel members being provided with summative results and collated, anonymised comments at the commencement of Rounds 2 and 3. Results Ninety panel members were recruited (64.3% of target), with high participation levels throughout the three Delphi rounds (91.1%, 83.3%, 72.2%). During Round 1, consensus was obtained for 27/46 statements (58.7%), with an additional two statements in Round 2 and none in Round 3. Consensus was obtained for statements relating to: potential gain arising from polypharmacy management (3/4 statements); strategic development (7/7); change management (5/7) indicator measures (4/6); legislation (0/3); awareness raising (5/5); polypharmacy reviews (5/7); and EU vision (0/7). Analysis of free text comments indicated that the vision statements were too ambitious and not achievable by the specified timeframe of 2025. Conclusion Consensus was obtained amongst key EU strategists around many aspects of polypharmacy management in older people. Notably, no consensus was achieved in relation to statements relating to the need to alter legislation in areas of healthcare delivery, remuneration and practitioner scope of practice. While the vision for the EU by 2025 was considered rather ambitious, there is great potential and clear opportunity to advance polypharmacy management throughout the EU and beyond.


PLOS ONE | 2018

A case study of polypharmacy management in nine European countries: implications for change management and implementation.

Jennifer McIntosh; Albert Alonso; Katie MacLure; Derek Stewart; Thomas Kempen; Alpana Mair; Margarida Castel-Branco; Carles Codina; Fernando Fernandez-Llimos; Glenda Fleming; Dimitra Gennimata; Ulrika Gillespie; Cathy Harrison; Maddalena Illario; Ulrike Junius-Walker; Christos F. Kampolis; Przemyslaw Kardas; Pawel Lewek; João O. Malva; Enrica Menditto; Claire Scullin; Birgitt Wiese

Background Multimorbidity and its associated polypharmacy contribute to an increase in adverse drug events, hospitalizations, and healthcare spending. This study aimed to address: what exists regarding polypharmacy management in the European Union (EU); why programs were, or were not, developed; and, how identified initiatives were developed, implemented, and sustained. Methods Change management principles (Kotter) and normalization process theory (NPT) informed data collection and analysis. Nine case studies were conducted in eight EU countries: Germany (Lower Saxony), Greece, Italy (Campania), Poland, Portugal, Spain (Catalonia), Sweden (Uppsala), and the United Kingdom (Northern Ireland and Scotland). The workflow included a review of country/region specific polypharmacy policies, key informant interviews with stakeholders involved in policy development and implementation and, focus groups of clinicians and managers. Data were analyzed using thematic analysis of individual cases and framework analysis across cases. Results Polypharmacy initiatives were identified in five regions (Catalonia, Lower Saxony, Northern Ireland, Scotland, and Uppsala) and included all care settings. There was agreement, even in cases without initiatives, that polypharmacy is a significant issue to address. Common themes regarding the development and implementation of polypharmacy management initiatives were: locally adapted solutions, organizational culture supporting innovation and teamwork, adequate workforce training, multidisciplinary teams, changes in workflow, redefinition of roles and responsibilities of professionals, policies and legislation supporting the initiative, and data management and information and communication systems to assist development and implementation. Depending on the setting, these were considered either facilitators or barriers to implementation. Conclusion Within the studied EU countries, polypharmacy management was not widely addressed. These results highlight the importance of change management and theory-based implementation strategies, and provide examples of polypharmacy management initiatives that can assist managers and policymakers in developing new programs or scaling up existing ones, particularly in places currently lacking such initiatives.


British Journal of Clinical Pharmacology | 2012

A new taxonomy for describing and defining adherence to medications.

Bernard Vrijens; Sabina De Geest; Dyfrig A. Hughes; Kardas Przemyslaw; Jenny Demonceau; Todd M. Ruppar; Fabienne Dobbels; Emily Fargher; Val Morrison; Pawel Lewek; Michał Matyjaszczyk; Comfort Mshelia; Wendy Clyne; Jeffrey Aronson; John Urquhart


Drugs | 2013

Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis.

Jenny Demonceau; Todd M. Ruppar; Paulus Kristanto; Dyfrig A. Hughes; Emily Fargher; Przemyslaw Kardas; Sabina De Geest; Fabienne Dobbels; Pawel Lewek; John Urquhart; Bernard Vrijens


Journal of Family Practice | 2010

Generic drugs: the benefits and risks of making the switch.

Pawel Lewek; Przemyslaw Kardas

Collaboration


Dive into the Pawel Lewek's collaboration.

Top Co-Authors

Avatar

Przemyslaw Kardas

Medical University of Łódź

View shared research outputs
Top Co-Authors

Avatar

Michał Matyjaszczyk

Medical University of Łódź

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fabienne Dobbels

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John Urquhart

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Derek Stewart

Robert Gordon University

View shared research outputs
Researchain Logo
Decentralizing Knowledge